SecBot SecBot

PHAR drug pipeline

Pharming Group N.V. · 3 rated drugs
$12.59
−0.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±8.8%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
3
1 bullish · 2 neutral
Phase 3 trials
2
1 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and commercializing (first FDA approval March 2023). Label expansion for children 4-11 approved September 2026 with new doses available October 2026. EU launch starting Germany Q3 2026.

Joenja leniolisib Updated Sep 12

What to watch

Joenja's commercial ramp is the key story, watch quarterly Joenja revenue growth, EU launch uptake (starting Germany Q3 2026), and the pending sNDA for lower-weight pediatric patients (13kg to <27kg) submitted July 30, 2026. Phase 3 topline data for ages 1-6 (trial NCT05693129, primary completion July 2026) and Phase 2 CVID data (expected Q4 2026) are potential catalysts. The stock's 52-week low of $9.62 vs. analyst mean target of $34.35 suggests deep value if Joenja execution holds, but the company also faces headwinds from RUCONEST decline and recent revenue guidance cuts.

Bull case
  • Joenja is the first and only approved treatment for APDS, an ultra-rare disease with no direct competitors, strong pricing and orphan drug protections
  • Revenue growing rapidly: $14.1M (Q1 2026, +34% YoY) and $17.9M (Q2 2026, +40% YoY), with label expansion to children 4-11 and EU/Japan launches adding new patient segments
  • Analyst consensus overwhelmingly bullish: 13 of 14 analysts at Buy/Strong Buy, mean price target $34.35 vs. current ~$11.21 (234% implied upside)
Bear case
  • RUCONEST franchise (hereditary angioedema) is Pharming's larger revenue driver but declining 10-15% YoY, dragging total company growth
  • Company lowered 2026 revenue guidance by $30M to $375M-$395M in Q2 2026, and operating profit collapsed to $1.3M from $10.8M a year ago
  • Institutional holders are trimming: NewEdge Advisors near-exited (-91.3%), OSAIC near-exited (-87.5%), BNP Paribas trimmed (-25%) in Q2 2026
● neutral
Impact
PhaseUnknown (early-stage/preclinical or Phase 1)
Time to marketUnknown — FALCON trial enrollment expected to complete H1 2027, topline results ~H1 2028 at earliest, followed by potential regulatory filing

Napazimone Updated Oct 24

What to watch

Napazimone is a very early-stage pipeline asset with no near-term binary catalyst. Pharming's near-term value drivers are its approved products RUCONEST and Joenja (leniolisib), plus the upcoming Phase II CVID readout for leniolisib in November 2026 and the Joenja pediatric sNDA PDUFA on January 30, 2027. Napazimone is not investable as a standalone catalyst at this stage.

Bull case
  • Pharming is a commercial-stage company with growing revenue (~US$117.6M in Q3 2026, +21% YoY) from two approved products, providing financial stability to fund pipeline development.
  • The FALCON trial enrollment completion in H1 2027, while delayed, indicates the program is still active and progressing.
  • Pharming has strong analyst support (12 Buy/Strong Buy vs 1 Hold, mean price target ~US$34.35 implying ~207% upside from ~US$11.20).
Bear case
  • Napazimone is extremely early-stage with essentially no public clinical data, its mechanism, phase, and target indication are not confirmed in any publicly available source.
  • The FALCON trial has already experienced enrollment delays (pushed to H1 2027), suggesting potential development challenges.
  • Pharming's pipeline focus appears to be on leniolisib label expansion (APDS pediatric, CVID, genetic PIDs), making napazimone a lower-priority asset.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially marketed (FDA-approved since 2014)

RUCONEST conestat alfa Updated Oct 24

What to watch

RUCONEST is a mature, approved product with no pending binary catalyst for this specific drug. The next company-wide catalysts are the full Q3 2026 earnings on October 27 and the leniolisib CVID Phase II topline in November 2026, but those are for Joenja, not RUCONEST. Watch RUCONEST's revenue trajectory (Q3 showed +14% growth) and whether the inventory-driven rebound is sustainable against competitive pressure from newer HAE therapies.

Bull case
  • RUCONEST remains Pharming's largest revenue contributor, Q3 2026 preliminary revenue of ~$93.8M (+14% YoY, +30% QoQ) showed a strong rebound from H1 weakness, partly from seasonal channel inventory build.
  • Analyst consensus is Strong Buy (6 buy, 1 hold, 0 sell; 6 strong buy, 0 strong sell) with a mean price target of $34.35, implying ~234.8% upside from the current ~$11.20 stock price.
  • RUCONEST is a well-established, approved recombinant therapy for HAE with a known safety profile and stable commercial infrastructure supporting the company's profitability.
Bear case
  • RUCONEST revenue is declining on a YoY basis, down 15% in Q1 2026 and 10% in Q2 2026, pressured by inventory drawdowns, market exits and competition from newer HAE therapies like Takhzyro (lanadelumab) and Firazyr (icatibant).
  • Pharming's pipeline is shifting toward Joenja (leniolisib) as the growth driver; RUCONEST's commercial peak may be behind it as the HAE market shifts toward prophylactic treatments.
  • The stock is down ~48% from its 52-week high of $21.34, and the technical composite score is neutral (-13.75) with price 19.65% below the 200-day SMA, indicating persistent weakness.

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Mar 24, 2023JoenjaApproval+8.8%+19.8%

Clinical trials

5 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
JoenjaLeniolisib for Immune Dysregulation in CVIDPhase 2Completed27Aug 12, 2026
JoenjaPediatric Patients Aged 1 to 6 Years With APDSPhase 3Active not recruiting16Jul 9, 2026
JoenjaLeniolisib for Immune Dysregulation in PIDsPhase 2Completed13Jun 23, 2026
RUCONESTRecombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve ImplantationPhase 2Completed141Jan 5, 2026
JoenjaExtension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLIPhase 3Terminated · results37Jan 30, 2025